Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF vs TDF in HBeAg-Negative Chronic Hepatitis B
NCT01940341Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2013
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at 48 weeks. Started Sep 2013; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01940341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01940341.